MAP2K7 and melanoma: Melanoma is sensitive to immune checkpoint inhibitors (such as anti-CTLA4 and anti-PD1 monoclonal antibodies) and small-molecule targeted drugs (such as BRAF inhibitors and MEK inhibitors).